Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224476 | 1.00 | AADAT (0.46) | AADATPREPTMEM97SIGMAR1TGM2 | |
| SCHEMBL10117812 | 0.93 | AADAT (0.46) | AADATPREPTMEM97SIGMAR1TGM2 | |
| SCHEMBL38658062 | 0.83 | SCD5 (0.43) | — | |
| SCHEMBL19385191 | 0.83 | SCD5 (0.43) | — | |
| SCHEMBL19385192 | 0.83 | SCD5 (0.43) | — | |
| SCHEMBL19400882 | 0.81 | KMT2A (0.51) | ALDH1A1TSHRNPSR1 | |
| SCHEMBL29562728 | 0.81 | KMT2A (0.51) | ALDH1A1TSHRNPSR1 | |
| SCHEMBL19400899 | 0.81 | KMT2A (0.51) | ALDH1A1TSHRNPSR1 | |
| SCHEMBL38656664 | 0.81 | KMT2A (0.51) | ALDH1A1TSHRNPSR1 | |
| SCHEMBL3213021 | 0.79 | HCRTR1 (0.50) | AADATPREPTMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | AADAT 2338/4885PREP 113/4885TMEM97 4201/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | AADAT 2338/4885PREP 113/4885TMEM97 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.